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Research Paper
Affect, interpersonal behaviour and interpersonal 
perception during open-label, uncontrolled paroxetine 
treatment of people with social anxiety disorder:  
a pilot study
Lance M. Rappaport, PhD; Jennifer J. Russell, PhD; Donald Hedeker, PhD;  
Gilbert Pinard, MD; Pierre Bleau, MD; Debbie S. Moskowitz, PhD
Introduction
Social anxiety disorder (SAD), also known as social phobia, 
describes anxiety-related physiologic, cognitive and affective 
responses to social stimuli, such as interpersonal interac-
tions.1 Within the cognitive–behavioural formulation, fears 
about perceived or anticipated negative social outcomes 
drive physiologic and affective distress. This distress nega-
tively reinforces interpersonal behaviours (such as submis-
sive2,3 and quarrelsome behaviours4) that avoid the feared 
outcome by limiting social interaction.5 The resulting behav-
iours6 may be regarded negatively by others and result in 
negative social outcomes.7 Individuals with SAD report ex-
pecting negative evaluations from others, low expectations of 
their performance in social situations5 and a tendency to con-
strue social situations as threatening,8,9 including perceiving 
less closeness in interpersonal relationships and perceiving 
themselves as inferior and of lower social status.10
Serotonergic medications (e.g., selective serotonin reuptake 
inhibitors [SSRIs])11 have demonstrated effectiveness in treat-
ing symptoms of SAD. As well, SSRIs may modulate charac-
teristic affect, interpersonal behaviour and interpersonal per-
ceptions among people with SAD. For example, enhanced 
serotonergic function through the administration of trypto-
phan,12 SSRIs13 or serotonin and norepinephrine reuptake in-
hibitors (SNRIs)14,15 augments warm-agreeableness13–18 and 
dominance,13,15,19 decreases within-person variability20 and re-
duces aggression in nonhuman primates21 and humans.22 Ad-
ditionally, administration of SSRIs and tryptophan to healthy 
and depressed individuals21,22 increases awareness of and 
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Background: Laboratory-based research with community samples has suggested changes in affective, behavioural and cognitive pro-
cesses as possible explanations for the effects of serotonergic medications. Examining the effects of serotonergic medications using an 
ecological momentary measure (such as event-contingent recording) in the daily lives of people with social anxiety disorder would con-
tribute to establishing the effects of these medications on affect, behaviour and one form of cognition: perception of others’ behaviour. 
Methods: The present study assessed changes in affect, interpersonal behaviour and perception of others’ behaviour in adults with so-
cial anxiety disorder using ecological momentary assessment at baseline and over 4 months of a single-arm, uncontrolled, open-label 
trial of treatment with the selective serotonin reuptake inhibitor paroxetine. Results: Anxiety and concurrent depressive symptoms de-
creased. Participants also reported increased positive and decreased negative affect; increased agreeable and decreased quarrelsome 
behaviour; increased dominant and decreased submissive behaviour; and increased perception that others behaved agreeably toward 
them. Moreover, participants demonstrated reduced intraindividual variability in affect, interpersonal behaviour and perception of others’ 
behaviour. Limitations: Limitations included the lack of a placebo group, the inability to identify the temporal order of changes and the 
restricted assessment of extreme behaviour. Conclusion: The results of the present study demonstrate changes during pharmacother-
apy in the manifestation of affect, interpersonal behaviour and interpersonal perception in the daily lives of people with social anxiety dis-
order. Given the importance of interpersonal processes to social anxiety disorder, these results may guide future research seeking to 
clarify mechanisms of action for serotonergic medications.
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 attention to positive social cues, such as perceiving ambigu-
ous stimuli as positive.
Affect, behaviour and perceptions related to SAD may con-
tribute to its maintenance, and modification of these patterns 
may indicate a mechanism of action to explain the anxiety-
reducing effect of serotonergic treatments. The Social Interac-
tion Model proposed by Young and colleagues23 focuses on 
depression and suggests that serotonergic medication in-
creases prosocial behaviour and reduces instability, thereby 
improving social interactions that reduce symptomatology.24 
Among healthy volunteers, research has documented changes 
in interpersonal behaviour13–15,18,25 and participant-reported 
interpersonal problems26 during the administration of seroto-
nergic medications. Harmer and colleagues27,28 summarized 
evidence supporting a cognitive neuropsychological model, 
in which serotonergic medication facilitates changes in atten-
tion and memory that reduce cognitive biases. Changes in 
 attention and memory on laboratory-based facial emotion 
recognition tasks has been found among healthy volunteers29 
and clinical samples.23 Empirical support for these proposals 
is indicated from research with healthy volunteers but is lim-
ited in clinical samples.
While both self-report and laboratory-based research have 
unique strengths, they also have limitations, including retro-
spective recall bias for self-reports completed long (e.g., 
weeks) after the event of interest and limited generalizability 
of laboratory tasks to the range of situations encountered in 
daily life.30 For example, Tse and Bond13,15 provided critical 
initial indications that, among healthy volunteers, SSRI or 
SNRI administration may increase agreeable–cooperative be-
haviour and decrease submissive behaviour in participants’ 
daily lives. This work relied on flatmate reports of participant 
behaviour, which improved ecological validity but relied on 
retrospection. Moreover, this kind of method focuses on how 
the person behaves in general, but is unable to examine tem-
poral patterns such as intraindividual variability. To further 
examine whether changes in affect, cognition and interper-
sonal behaviour are potential mechanisms of action for sero-
tonergic pharmacotherapy of SAD, investigation is needed 
with interventions using clinical samples.
Assessment of affect, interpersonal behaviour and percep-
tion in the daily lives of community and clinical samples has 
been refined over 30 years of research. Research on interper-
sonal behaviour and the perception of others has frequently 
conceptualized behaviour along the 2 dimensions (i.e., com-
munal [agreeable–quarrelsome] and agentic [dominant–
submissive]) of the interpersonal circumplex.31 Ecological 
momentary assessment (EMA) methods32 provide intensive 
repeated measures in naturalistic settings and are well-suited 
to examine changes in the naturalistic manifestation of affect, 
interpersonal behaviour and perception closely following in-
terpersonal interactions during pharmacological treatment.33 
The high temporal density of EMAs permits computing mea-
sures beyond mean level (e.g., intraindividual variability in 
affect, interpersonal behaviour and perception that indexes in-
stability34 and confers risk for anxiety35,36 and interpersonal 
problems37,38). Because EMAs ask participants to self-report on 
current states (e.g., affect), reports are minimally retrospective 
and assess temporal dynamics outside of awareness. For 
 example, one study demonstrated that tryptophan adminis-
tration to a community sample decreased intraindividual 
variability of interpersonal behaviour for irritable individ-
uals.20 Testing whether SSRI administration reduces variabil-
ity (i.e., instability) may clarify anxiety-reducing effects.
The present study
The present study sought to demonstrate change in mean 
level and intraindividual variability in affect, interpersonal 
behaviour and perception during serotonergic treatment of 
SAD. Given the importance of interpersonal situations for 
SAD, the present study assessed affect, interpersonal behav-
iour and perception during  naturally occurring interpersonal 
situations using event-contingent recording (ECR), a specific 
form of EMA. Participants recorded their affect, interpersonal 
behaviour and perception of others’ behaviour following 
interpersonal interactions that lasted longer than 5 minutes.39
This study was conducted in Canada following the princi-
ples of the Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans,40 which states that placebo-
controlled clinical trials can be conducted when participants 
are randomly assigned to different groups, and when there is 
equipoise or genuine uncertainty on the part of the relevant 
expert community about which therapy is most effective for a 
given condition. Given that paroxetine is approved for the 
treatment of SAD, there was no equipoise between parox-
etine and placebo. The use of a placebo group would not 
have conformed to the Tri-Council Policy Statement, so par-
oxetine was administered in an open-label design with no 
placebo or control condition.
This study provides a preliminary examination of 
changes in affect, interpersonal behaviour and perception 
during treatment with paroxetine, as manifested in the daily 
lives of people with SAD. Although further research is 
needed to examine affective, behavioural and cognitive pro-
cesses as clinical outcomes of paroxetine treatment, the pres-
ent study provides an initial examination of changes in both 
mean and intraindividual variability during paroxetine ad-
ministration. Because paroxetine is frequently used to treat 
SAD in clinical practice,11 the present study indicates changes 
in affect, interpersonal behaviour and interpersonal percep-
tion that may occur during psychiatric practice.
Based on the literature in human and nonhuman primates, 
we hypothesized that during paroxetine treatment partici-
pants would demonstrate elevated positive and reduced neg-
ative affect; elevated agreeable and decreased quarrelsome 
 behaviour; and elevated dominant and reduced submissive 
behaviour. Given evidence that SAD may be associated with a 
cognitive bias toward social threat8 that may decrease after 
SSRI administration,27,28 we hypothesized increased percep-
tion of warmth in others’ behaviour. We considered change in 
the perception of dominance in others’ behaviour to be ex-
ploratory. We further hypothesized that results would extend 
previous evidence20 of reduced intraindividual variability in 
affect, interpersonal behaviour and perception of others’ 
 behaviour during paroxetine administration.
Affect, cognition and behaviour during SSRI treatment
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Methods
Participants
We recruited participants from a previous study of SAD3 
and from community advertisements. After people had 
been screened for SAD symptoms by phone, they were in-
vited to an initial meeting that included a diagnostic assess-
ment. Inclusion criteria were the ability to understand study 
materials in English and a primary diagnosis of SAD. Exclu-
sion criteria were a concurrent diagnosis of bipolar or psy-
chotic disorder and a lack of suitability for paroxetine treat-
ment due to hypersensitivity or current use of monoamine 
oxidase inhibitors.
Of 52 individuals who attended the initial session, 48 en-
rolled in the study, of whom 9 withdrew before beginning 
paroxetine administration.
Twenty-nine participants (60.4%) completed the baseline 
assessment and 4 months of treatment. Four (8.3%) partici-
pants discontinued the study after 2 months, 4 (8.3%) after 
3 months and 2 (4.2%) after 4 months. Participants who with-
drew indicated lower baseline anxiety on the Social Phobia 
Scale (SPS; t34.23 = −2.14, d = −0.73, p = 0.04) and Liebowitz 
Social Anxiety Scale (LSAS; t36.02 = −2.52, d = −0.84, p = 0.02). 
We reran analyses adjusting for baseline SPS and LSAS 
scores. Results were unchanged and are presented without 
adjustment. Withdrawal was not associated with baseline 
anxiety on the Social Interaction Anxiety Scale (SIAS), de-
pression symptom severity, participant age, sex, language, 
level of education or employment status (all p > 0.10). 
Measures
Psychiatric diagnosis and clinical assessment
We used the Mini-International Neuropsychiatric Interview 
(MINI, version 5)41 to establish diagnoses of SAD and comor-
bid disorders. We assessed the severity of SAD symptoms 
during treatment via clinician report on the LSAS42 and via 
participant report on the SPS and the SIAS.43 The SIAS in-
cludes 2 reverse-coded items. We conducted analyses with 
both items removed. We obtained identical results when we 
reran analyses with both items included (see Appendix 1, 
available at jpn.ca/170141-a1). We assessed the severity of de-
pressive symptoms via clinician report on the Montgomery–
Åsberg Depression Rating Scale,44 which correlates highly 
with participant report. Inter-item reliability of all symptom 
assessments was high at each time point (α = 0.69–0.96).
Interpersonal behaviour
We assessed participant interpersonal behaviour as commu-
nal (i.e., agreeable and quarrelsome) and agentic (i.e., domi-
nant and submissive) behaviour from the interpersonal cir-
cumplex model.31 Participants indicated their behaviour at 
each event by endorsing behaviours representing those di-
mensions on the Social Behaviour Inventory (SBI).45 Items 
were summed and ipsatized at each event to centre reports 
within the event and individual.45 The SBI has demon-
strated moderate to high inter-item reliability, strong con-
vergent validity, high test–retest reliability39 and suitability 
for use in clinical samples.3 We derived intraindividual vari-
ability for each behaviour or dispersion in type of interper-
sonal behaviour reported (i.e., spin) from each participant’s 
event-level reports.46
Affect
Participants recorded event-level positive and negative affect 
on 9 items balanced for affective arousal.47 Items were aver-
aged at each event to compute event-level positive and nega-
tive affect. Inter-item reliability across the 5 waves of data 
collection was high for negative (α = 0.89–0.92) and positive 
affect (α = 0.95–0.97). 
Perception of others’ behaviour
At each event, participants reported their perception of the 
behaviour of the person or people they interacted with48 by 
placing a mark on a 9 × 9 grid derived from the 2 dimensions 
of the interpersonal circumplex model (i.e., communal and 
agentic behaviour).31 Inter-rater reliability, test–retest reliability 
and convergent validity have been demonstrated previously.48
Design
This study followed an open-label, single-arm, nonrandomized, 
uncontrolled design. We assessed symptom severity, 
 affect, interpersonal behaviour and perception of others’ 
behaviour using ECR in a measurement burst design. 
Over the 5-month study, participants received paroxetine 
controlled-release (Paxil CR) titrated from 12.5 mg/d to 
25 mg/d to minimize potential side effects. Participants 
met with the prescribing psychiatrist at 4-week intervals 
(i.e., at 4, 8, 12 and 16 weeks from the initiation of treat-
ment) to evaluate adverse effects and complete symptom 
assessments. Participants completed 1 week of the ECR 
procedure after each clinical meeting; by the end of the 
study, participants had completed 35 days of the ECR 
procedure over 5 periods of 1 week.
This report describes all measures and conditions. As 
 described previously, data were excluded if missing; partici-
pants were excluded based on inclusion and exclusion crite-
ria. Financial constraints dictated sample-size determination. 
Procedure
Following telephone screens, participants attended an infor-
mation session. During this baseline session, participants 
provided informed consent and participated in an in-person 
assessment conducted by study psychiatrists to establish 
psychi atric diagnosis and suitability for paroxetine treatment. 
Subsequently, participants began a baseline 1-week period of 
the ECR procedure (see below). For 2 participants drawn 
from a previously collected sample,3 the final week of a pre-
vious 20-day ECR procedure provided the baseline. 
Event-contingent recording
During each ECR period, participants were asked to com-
plete a form after each substantial interaction, defined as an 
Rappaport et al.
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interaction lasting longer than 5 minutes.39 Participants used 
the forms to report on their affect, their interpersonal behav-
iour and the behaviour of the person with whom they inter-
acted. To reduce participant burden, a subset of behaviour 
items were included on each form. To reduce the potential 
for participants to develop a response set over events, SBI 
items were rotated over days. There were 4 forms, each with 
3 items for each behaviour dimension.
Ethics 
This study was approved by the McGill University Re-
search Ethics Board. All procedures contributing to this 
work complied with the ethical standards of the relevant 
national and institutional committees on human experi-
mentation and with the Helsinki Declaration of 1975, as re-
vised in 2008. 
Statistical analysis
We fit a mixed-effects (i.e., multilevel) growth curve model 
to each measure of syndrome severity to evaluate change 
in the severity of anxiety and depressive symptoms over 
the 5 months of the study. 
We fit location–scale models to model change in the mean 
(i.e., location) and variance (i.e., scale) of interpersonal be-
haviour, affect and perception of others’ behaviour over 
time, while adjusting for correlation between the mean and 
variance.49 We used a 3-level mixed-effects  location–scale 
model, adapted from Hedeker and Mermelstein,50 to ac-
count for nesting of events within measurement wave (i.e., 
month), which were nested within person (see Appendix 1). 
Variance was log-transformed. Tables report original esti-
mates; the results section provides estimates exponen-
tiated to compute a variance ratio (VR) representing the 
 average proportion of change in variance each month. We 
assessed change in spin, an aggregate index of intraindi-
vidual variability in interpersonal behaviour,46 using a 
mixed-effects growth curve model. We then added 
monthly anx iety symptoms as main effects for both the 
mean and variance. Because of multicollinearity, we ran 
each model separately with each index of anxiety symp-
tomatology. Anxiety assessments were centred within- 
person.50 We  entered the person-level and centred scores 
as predictors, thereby disaggregating within- and  between- 
person  associations.
We conducted all analyses using SAS software version 9.451 
and maximum likelihood estimation with the NLMIXED pro-
cedure. We imported estimated fixed effects into R version 
3.2.352 and plotted them using the ggplot2 package.53
Results
Participants
Of the 39 participants who began paroxetine administration, 
19 (48.7%) were female. Participant ages ranged from 20 to 
60 years (mean ± standard deviation 33.92 ± 11.49). 
Psychiatric comorbidity was low but included concurrent 
dysthymic disorder (n = 1), recurrent major depressive disorder 
(n = 1), panic disorder (n = 1), alcohol abuse (n = 1) and sub-
stance abuse (n= 1). At baseline, all participants scored above a 
recommended clinical cutoff on the LSAS.54 Mean baseline anx-
iety severity (SPS and SIAS) was high relative to extant research 
on SAD.55 Baseline assessment of depressive symptoms 
(Montgomery–Åsberg Depression Rating Scale) indicated mild 
depressive symptoms (score > 10)56 in 10 participants (27%). 
The sample included 21 participants (53.8%) whose first 
language was English. Twelve participants (30.8%) reported 
employment at least 30 hours per week, 24 (61.5%) were em-
ployed less than 30 hours per week and 3 (7.7%) did not pro-
vide employment information. Sixteen participants (41.0%) 
had a bachelor’s degree, 15 (38.5%) had some college educa-
tion, 5 (12.9%) had high school education or less and 3 (7.7%) 
had a postgraduate degree. The distribution of educational 
makeup was similar to that of Montréal, Que., Canada, where 
the study was conducted.57
Change in symptoms
As expected, following initiation of paroxetine treatment, 
clinician-rated (i.e., LSAS) and participant-rated (i.e., SPS and 
SIAS) anxiety (Fig. 1A) and depressive symptoms (Fig. 1B) 
decreased. There was a monotonic downward pattern with 
deceleration over time (Table 1 and Appendix 1, Table S1, for 
random effects).
Change in affect
As hypothesized, over the course of treatment, participants 
reported increased positive and decreased negative affect 
(Table 2, Fig. 1C; see Appendix 1, Table S2, for random 
effects). Similar to the pattern of change in symptom severity, 
improvements in mean affect (e.g., decreased negative affect) 
decelerated over time. As hypothesized, intraindividual 
variability (i.e., variance, scale) in affect decreased over time 
for both positive and negative affect by 14% (VR = 0.86) and 
37% (VR = 0.63) per month, respectively (Fig. 1D).
Change in perception of others’ interpersonal behaviour
As hypothesized, participants’ tendency to perceive others as 
behaving agreeably increased. There was a decelerating rate 
of change over time (Table 2, Fig. 2A; see Appendix 1, Table 
S2, for random effects). Participants’ tendency to perceive 
others as behaving dominantly did not change over time. As 
hypothesized, intraindividual variability (i.e., variance, scale) 
in participants’ perceptions of warmth decreased over time 
by 16% (VR = 0.84) per month (Fig. 2B). Intraindividual 
variability in the perception of others’ dominant behaviour 
decreased over time by 21% (VR = 0.79) per month.
Change in participants’ interpersonal behaviour
As hypothesized, over time participants reported increased 
communal behaviour; agreeable behaviour increased while 
Affect, cognition and behaviour during SSRI treatment
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quarrelsome behaviour decreased (Table 2, Fig. 2C; see 
Appendix 1, Table S3, for random effects). In addition, 
agentic behaviour increased as reflected in increased domi-
nant and decreased submissive behaviour. Improvements 
in agreeable, quarrelsome and submissive behaviour decel-
erated over time, though dominant behaviour increased at 
a steady rate. As hypothesized, variability in participant 
reports of interpersonal behaviour across interactions de-
creased for agreeable, quarrelsome, dominant and sub-
missive behaviour by 5% (VR = 0.95), 9% (VR = 0.91), 6% 
(VR = 0.94) and 14% (VR = 0.86) per month, respectively 
(Fig. 2D). Spin, which reflects dispersion in interpersonal 
behaviour,46 also decreased in a linear trajectory over time 
(B = −0.10, p < 0.001, 95% confidence interval −0.15 to 
−0.06), even after adjusting for concurrent mean communal 
and agentic behaviour.
Change in the mean-squared successive difference
Additional mixed-effects growth curve models were fit 
to estimate change in intraindividual variability in affect, 
perception of others’ interpersonal behaviour and partici-
pants’ interpersonal behaviour when computed as the 
mean-squared successive difference. Results were consis-
tent with the location–scale approach for positive and 
negative affect, perception of others’ behaviour as domi-
nant and warm, and participants’ agreeable and submis-
sive behaviour. 
Fig. 1: Changes in symptom severity (A, B) and event-level affect mean and variability (C, D). LSAS = Liebowitz Social Anxiety Scale; 
MADRS = Montgomery–Åsberg Depression Rating Scale; SIAS = Social Interaction and Anxiety Scale; SPS = Social Phobia Scale.
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Discussion
During 4-month treatment with paroxetine, people with SAD 
reported improved mood (i.e., increased positive and decreased 
negative affect), greater affiliative/communal behaviour (i.e., 
increased agreeable and decreased quarrelsome behaviour) 
and increased agentic behaviour (i.e., increased dominant 
and reduced submissive behaviour). Participants perceived 
others’ behaviour as increasingly warm. They also demon-
strated decreased intraindividual variability in affect, inter-
personal behaviour and perception of others’ behaviour. 
Anxiety and depressive symptomatology decreased as mea-
sured by both participant and clinician report.
Because it lacked a placebo control, the present study pro-
vides only preliminary evidence that serotonin modulation 
influences affect, interpersonal behaviour and interpersonal 
perception. However, results are consistent with previous 
findings. For example, evidence of decreased quarrelsome 
behaviour during paroxetine administration extends evidence 
among nonclinical community participants16,25 that adminis-
tration of tryptophan, a serotonin precursor,12 decreased quar-
relsome behaviour in daily life compared with placebo. 
Similarly, evidence of increased agreeable behaviour is con-
sistent with previous research in nonhuman primates17 and 
healthy human participants during a laboratory cooperation 
task13–15,18 and naturalistic assessment.15,16 The present find-
ings further implicate serotonin in the modulation of agentic 
behaviour. This is consistent with increased dominant16,25 
and reduced submissive behaviour13,15 following tryptophan 
and SSRI/SNRI administration to healthy human partici-
pants, respectively.
Beyond mean behavioural patterns, intensive repeated-
measures methodologies such as ECR permit assessment of 
intraindividual variability in participant-reported affect, 
behaviour and perceptions over the range of situations ex-
perienced in daily life.46 Elevated variability, which has 
been associated with general anxiety34–36,58 and SAD,59 may 
be associated with interpersonal difficulties.37,38 Prior research 
demonstrated reduced intraindividual variability in interper-
sonal behaviour following tryptophan administration com-
pared with placebo among healthy participants with elevated 
irritability.20 The present study further suggests reduced 
intraindividual variability in affect, behaviour and perception 
during paroxetine administration.
Table 1: Change in anxiety and depression symptom severity over treatment
Scale Intercept, B (95% CI) Linear slope, B (95% CI) Quadratic slope, B (95% CI)
Liebowitz Social Anxiety Scale 116.38*** (106.31 to 126.45) −35.52*** (−43.06 to −27.97) 4.03*** (2.81 to 5.25)
Social Phobia Scale 61.85*** (55.65 to 68.05) −18.26*** (−22.19 to −14.33) 2.01*** (1.39 to 2.63)
Social Interaction and Anxiety Scale 63.96*** (59.16 to 68.76) −17.67*** (−21.34 to −14.01) 1.92*** (1.34 to 2.50)
Montgomery−Åsberg Depression Rating Scale 9.74*** (6.91 to 12.57) −3.07** (−5.25 to −0.89) 0.34 (−0.02 to 0.70)
CI = confidence interval. 
**p ≤ 0.01; ***p ≤ 0.001. 
For random-effect estimates, see Appendix 1, Table S1, available at jpn.ca/170141-a1.
Table 2: Change in affect, perception and interpersonal behaviour over treatment, mean (location) and variance (scale)
Measure
Mean Variance
Intercept, B/σ2  
(95% CI)
Linear slope, B/σ2 
(95% CI)
Quadratic slope, B/σ2 
(95% CI)
Cubic slope, B/σ2 
(95% CI)
Intercept, B/σ2 
(95% CI)
Linear slope, B/σ2  
(95% CI)
Positive affect 2.21***  
(1.89 to 2.52)
0.47***  
(0.29 to 0.65)
−0.08***  
(−0.13 to −0.04)
— 0.18  
(−0.01 to 0.37)
−0.15***  
(−0.19 to −0.11)
Negative affect 1.32***
(1.12 to 1.51)
−0.51***
(−0.62 to −0.39)
0.08***
(0.06 to 0.11)
— −0.18
(−0.49 to 0.13)
−0.47***  
(−0.51 to −0.44)
Perception of warmth 7.39***
(7.02 to 7.75)
0.67***
(0.41 to 0.93)
−0.10**
(−0.16 to −0.04)
— 1.76***
(1.56 to 1.97)
−0.18***  
(−0.22 to −0.14)
Perception of dominance 7.63***  
(7.37 to 7.88)
— — — 1.56***
(1.36 to 1.77)
−0.23***  
(−0.27 to −0.19)
Agreeable behaviour 11.83***
(9.36 to 14.29)
5.22***
(2.94 to 7.51)
−1.06***
(−1.62 to −0.50)
— 6.30***
(6.22 to 6.39)
−0.05**  
(−0.08 to −0.01)
Quarrelsome behaviour −15.21***
(−17.58 to −12.83)
−1.82*
(−3.47 to −0.17)
0.40*
(−0.003 to 0.81)
— 6.00***
(5.84 to 6.16)
−0.09***  
(−0.13 to −0.06)
Dominant behaviour −0.88
(−3.68 to 1.92)
2.21***
(1.27 to 3.15)
— — 6.30***
(6.20 to 6.39)
−0.06**
(−0.09 to −0.02)
Submissive behaviour 3.83*
(0.47 to 7.18)
−14.28***
(−20.05 to −8.51)
6.18**
(2.45 to 9.91)
−0.88**
(−1.50 to −0.25)
6.52***
(6.41 to 6.64)
−0.15***
(−0.19 to −0.12)
CI = confidence interval.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
Dashes indicate a nonsignificant effect not included in the final model. 
For random-effect estimates, see Appendix 1, Table S2 and Table S3, available at jpn.ca/170141-a1.
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The changes reported during paroxetine treatment in the 
present study parallel affective, behavioural and cognitive 
deficits characteristics of SAD. Reduced submissive behav-
iour2,3 and increased agreeable behaviour4 may decrease 
 interpersonal stress in close relationships.7 Increases in the 
perception of warmth in others’ behaviour are consistent 
with construing social situations as less threatening,8 and 
 expecting less negative evaluation from others could contrib-
ute specifically to reduced anxiety and more generally to 
 reduced negative affect.5
Change in interpersonal behaviour and perceptions of 
 others’ behaviour is consistent with 2 recent proposals for be-
havioural and cognitive mechanisms of serotonergic pharma-
cotherapy. Increased communal and agentic behaviour is 
consistent with the Social Interaction Model, which suggests 
that symptom improvement may result from improved inter-
personal behaviour and, subsequently, reduced negative 
 interpersonal consequences.24 Evidence of increased percep-
tion of warmth in others’ behaviour, along with improved 
 affect, supports the Cognitive Neuropsychological Model, in 
which serotonergic medication impacts on mood and symp-
tomatology by modifying cognitions, such as the tendency to 
perceive others as acting in a quarrelsome manner.27,28
Previous support for both theories has been limited to re-
search in healthy community participants or laboratory-
based research. While the present findings do not support 
one model more strongly than the other, they provide the 
first evidence to demonstrate changes in naturally occurring 
Fig. 2: Changes in mean and variability of participants’ perception of others’ behaviour (A, B) and participants’ own interpersonal behaviour (C, D). 
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patterns of affect, interpersonal behaviour and perception 
during SSRI treatment of individuals diagnosed with SAD. 
Future research is needed to rule out potential concomitants, 
such as the influence of reflecting on one’s interactions dur-
ing ECR data collection. Nonetheless, the present study pro-
vides an important initial step to demonstrate consistent 
changes in mean affect, interpersonal behaviour and percep-
tion of others’ behaviour, as well as reduction in intraindivid-
ual variability.
Limitations
Several limitations warrant consideration and further re-
search. The present study provides a preliminary investiga-
tion of change in affect, interpersonal behaviour and interper-
sonal perception without a comparison placebo condition. 
While the present study suggests changes during standard 
pharmacological treatment of individuals with SAD, future 
research is needed to rule out alternative explanations, such 
as the possibility that change is due to reflection on one’s in-
teractions. However, among community adults, previous re-
search has demonstrated moderate to high stability over con-
secutive weeks of the ECR measures used in the present 
study, which suggests that the procedure may not substan-
tially influence participants’ reported affect and behaviour.39,46
During paroxetine treatment, participants reported that 
others behaved more agreeably. This finding may indicate 
changes in participants’ perception of others’ behaviour or 
it may signify actual changes in others’ behaviour. Addi-
tionally, previous work has implicated affect and others’ 
behaviour in modulating participants’ behaviour.58,60 
 Future use of the ECR procedure and related EMA method-
ology is needed to examine the temporal patterning of 
changes in affect, interpersonal behaviour and perception 
of others’ behaviour.
The SBI and Interpersonal Grid assess the range of inter-
personal behaviours manifested in typical interpersonal 
 interactions among community participants.45,48 While these 
measures inform research with clinical samples, they may 
not include clinically relevant behaviours. For example, evi-
dence implicating serotonergic dysregulation in aggression 
suggests future research on changes in aggression beyond 
quarrelsome behaviour.
Conclusion
In the present study, individuals with SAD demonstrated in-
creased communal (more agreeable, less quarrelsome) and 
increased agentic (more dominant, less submissive) behav-
iours, improved affect and greater perception of warmth in 
others’ behaviour during SSRI pharmacotherapy for SAD. 
Moreover, participants demonstrated decreased intraindivid-
ual variability across all 8 measures of behaviour, affect and 
perception, which suggests reduced instability.
Although further research is needed, the present findings 
provide preliminary evidence of reductions in characteris-
tic affective, behavioural and perceptual patterns among 
individuals with SAD during pharmacotherapy with par-
oxetine. Findings also encourage the use of repeated assess-
ment of patients’ experiences in daily life. This method-
ological approach enhanced generalizability through 
naturalistic assessment across a range of interpersonal en-
counters. High temporal density recording permitted not 
only the assessment of mean levels, but also intraindivid-
ual variability in patient characteristics, a novel approach 
to the representation of patients’ features. As piloted in the 
present study, the assessment of symptoms and clinical 
outcomes in real time may inform the development of per-
sonalized treatments and provide novel indices of treat-
ment response, such as reduced affective, behavioural or 
cognitive variability.
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